Actively Recruiting
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Led by Revolution Medicines, Inc. · Updated on 2026-05-12
370
Participants Needed
5
Research Sites
169 weeks
Total Duration
On this page
Sponsors
R
Revolution Medicines, Inc.
Lead Sponsor
S
Summit Therapeutics
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RAS(ON) inhibitors in combination with ivonescimab in adults with advanced or metastatic solid tumors with a RAS mutation.
CONDITIONS
Official Title
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- At least 18 years old and has provided informed consent.
- ECOG performance status of 0 or 1.
- Histologically confirmed, locally advanced or metastatic solid tumor with documented RAS mutation in KRAS, HRAS, or NRAS.
- Received and progressed on or were intolerant to prior standard therapy (for Part 1 Dose Exploration).
- Non-squamous NSCLC without treatable driver mutations and no prior systemic treatment (Arms A & B for Part 2 Dose Expansion).
- Solid tumor or CRC treated with no more than 2 prior lines for advanced disease and progressed on or intolerant to prior standard therapies (Arm C for Part 2 Dose Expansion).
- Measurable disease per RECIST v1.1.
- Adequate organ function including bone marrow, liver, kidney, coagulation, and endocrine.
- Able to take oral medications.
You will not qualify if you...
- Head and neck squamous cell carcinoma.
- Conditions affecting ability to take or absorb study drugs.
- Major surgery within 4 weeks prior to receiving study drugs.
- Unable or unwilling to comply with study visits or procedures.
- Other inclusion/exclusion criteria may apply.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 5 locations
1
Eastern Connecticut Hematology and Oncology Associates
Norwich, Connecticut, United States, 06360
Actively Recruiting
2
Tennessee Oncology
Nashville, Tennessee, United States, 37023
Actively Recruiting
3
NEXT Dallas
Irving, Texas, United States, 75039
Actively Recruiting
4
NEXT Oncology
San Antonio, Texas, United States, 78229
Actively Recruiting
5
NEXT Virginia
Fairfax, Virginia, United States, 22031
Actively Recruiting
Research Team
R
Revolution Medicines Study Director
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here